Emanuela Marchesi

Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial

Alessandro Gronchi, Stefano Ferrari, Vittorio Quagliuolo et al. · The Lancet Oncology · 2017 · 489 citations

Medicine, Oncology, Surgery +17

Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial

Giovanni Grignani, Emanuela Palmerini, Virginia Ferraresi et al. · The Lancet Oncology · 2014 · 335 citations · Full text

Medicine, Oncology, Pharmacotherapy +9

Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups

Alessandro Gronchi, Emanuela Palmerini, Vittorio Quagliuolo et al. · Journal of Clinical Oncology · 2020 · 261 citations · Full text

Medicine, Oncology, Pharmacology +17

Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?

Emanuela Palmerini, Neal Shiv Chawla, Stefano Ferrari et al. · European Journal of Cancer · 2017 · 166 citations

Medicine, Oncology, Surgery +12

Photoreduction of the fluorescent dye 2′-7′-dichlorofluorescein: a spin trapping and direct electron spin resonance study with implications for oxidative stress measurements

Emanuela Marchesi, Cristina Rota, Yang C. Fann et al. · Free Radical Biology and Medicine · 1999 · 162 citations

Natural Sciences, Biophysics, Chemistry +16